Adjuvant immunotherapy (BCG) in stage D prostate cancer.
Thirty-three patients with advanced prostate cancer were prospectively randomized to receive either Bacillus Calmette-Guerin (BCG) adjuvant immunotherapy plus conventional therapy or conventional therapy alone. Conventional therapy consisted of estrogens or observation. There was a statistically significantly (p less than 0.05) longer survival in the 16 BCG-treated patients (42 weeks) than in the 17 control patients (29 weeks).
D000230:Adenocarcinoma / Q000628:therapy*; D000368:Aged; D001500:BCG Vaccine / Q000627:therapeutic use*; D002369:Castration; D004967:Estrogens / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000628:therapy*; D011897:Random Allocation
D001500:BCG Vaccine; D004967:Estrogens